Samuel Beavers is a partner in Goodwin’s internationally recognized Life Sciences group, specializing in complex transactions including mergers and acquisitions, venture capital financings, and joint ventures for companies at all stages of development. Sam also acts as outside general corporate counsel, providing guidance on commercial contracts and day-to-day corporate governance matters. He has been named as one of the “Best Lawyers in America” for his expertise in mergers and acquisitions.
Sam has experience with a broad range of corporate and transactional matters including company formation, business structuring, drafting and negotiating contracts, venture capital and growth equity financings, mergers and acquisitions, “US flips”, royalty monetizations, commercial transactions, capital markets, corporate governance and general corporate matters.
Sam received his JD cum laude from The Ohio State University, where he was a managing editor on the Ohio State Journal on Dispute Resolution. He also attended OSU for his Bachelor of Arts degree, while serving as a Specialist in the Ohio National Guard.
Representative Matters
- Advised Ironshore Therapeutics on its acquisition by Collegium Pharmaceutical for $525 million upfront and a potential $25 million commercial milestone payment
- Advised Medpharm on its combination with Tergus Pharma
- Advised Mariana Oncology on its acquisition by Novartis for $1 billion upfront and up to $750 million in potential milestone payments
- Advised Acino on its acquisition of M8 Pharmaceuticals
- Advised Mitokinin on its sale to AbbVie
- Advised Alkermes in the spin-off of its oncology business into Mural Oncology as a separate public company
- Advised ETM Electromatic, Inc. in its agreement to be acquired by Teledyne Technologies
- Advised Biocon Biologics Ltd. in its $3.335 billion (cash up to $2.335 billion plus stock in BBL valued at $1 billion) agreement to acquire Viatris Inc.’s (NASDAQ: VTRS) global biosimilars business
- Advised Royalty Pharma on its funding agreement and royalty acquisition with Cytokinetics for up to $450 million
- Advised ModeX Therapeutics, Inc. on its sale to OPKO Health, Inc. for $300 million in OPKO common stock
- Advised Dascena on the sale of its laboratory business to Cirrus DX
- Advised Pheon Therapeutics on its $120 million Series B financing
- Advised Meacor on its $15 Million Series A financing to advance its innovative transcatheter heart valve repair technology
- Advised Rapport Therapeutics in its $174.4 million initial public offering and concurrent private placement
- Advised Cerevance in its $47 million Series B-1 financing extension
- Advised Clarametyx Biosciences in its $33 million Series A financing
- Advised Enspire DBS Therapy in its $17.6 million Series B financing
- Advised Rapport Therapeutics in its $150 million Series B financing
- Advised Entact Bio, Inc. on its Series A financing
- Advised Heranova Lifesciences on its Series Seed financing
- Advised Reset Pharmaceuticals, Inc. on its Series A financing
- Advised Astoria Biologica, Inc. in its financing with Cure.Bio
- 5AM Ventures and Frazier Healthcare Partners as lead investors in the creation and $30 million financing of Radionetics Oncology
Professional Experience
Prior to joining Goodwin, Sam was an associate in the Business Group at Ice Miller LLP in Columbus, Ohio, and served in the Ohio National Guard.
Credentials
Education
JD2014
The Ohio State University
Moritz College of Law
BA2010
The Ohio State University
Admissions
Bars
- District of Columbia
- Ohio
Recognition & Awards
Sam was named one of the “Best Lawyers in America” for his expertise in mergers and acquisitions in 2024. In law school, he was a managing editor on the Ohio State Journal on Dispute Resolution.